Periprocedural abciximab administration in ST elevation myocardial infarction patients: Effect on severe microvascular obstruction beyond the restoration of epicardial coronary flow by primary angioplasty

Cardiology

Volumn 110, Issue 2, 2008, Pages 129-134

  Tarantini, Giuseppe ^a,b   Ramondo, Angelo ^a   Corbetti, Francesco ^a   Perazzolo Marra, Martina ^a   Cacciavillani, Luisa ^a   Napodano, Massimo ^a   Bilato, Claudio ^a   Razzolini, Renato ^a   Iliceto, Sabino ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Abciximab; Angioplasty; Myocardial infarction; Reperfusion

Indexed keywords

ABCIXIMAB; GADOBENATE DIMEGLUMINE;

ADULT; AGED; ANGIOPLASTY; ARTICLE; BLOOD VESSEL OCCLUSION; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DISEASE SEVERITY; FEMALE; HEART INFARCTION; HUMAN; MALE; NECROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; ST SEGMENT ELEVATION;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; CORONARY ANGIOGRAPHY; CORONARY CIRCULATION; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; MYOCARDIUM; NECROSIS; PLATELET AGGREGATION INHIBITORS; TIME FACTORS;

EID: 43049109538     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000110492     Document Type: Article

References (29)

1. Reiner JS, Lundergan CF, Fung A, et al: Evolution of early TIMI 2 flow after thrombolysis for acute myocardial infarction. Circulation 1996;94:2441-2446.
2. Tarantini G, Cacciavillani L, Corbetti F, et al: Duration of ischemia is a major determinant of transmurality and severe microvascular obstruction after primary angioplasty. A study performed with contrast enhanced magnetic resonance. J Am Coll Cardiol 2005;46:1229-1235.
3. Reffelman T, Hale SL, Li G, Kloner RA: Relationship between no reflow and infarct size as influenced by duration of ischemia and reperfusion. Am J Physiol 2002;282:H766-H772.
4. Montalescot G, Barragan P, Wittemberg O, et al: Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-1903.
5. Montalescot G, Borentain M, Payot L, et al: Early versus late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST segment elevation myocardial infarction. JAMA 2004;292:362-366.
6. De Luca G, Ernst N, Zijlstra F, et al: Preprocedural TIMI flow and mortality in patients with acute myocardial infarction treated by primary angioplasty. J Am Coll Cardiol 2004;43:1363-1367.
7. Godicke J, Flather M, Noc M, et al: Early versus periprocedural administration of abciximab for primary angioplasy: a pooled analysis of 6 studies. Am Heart J 2005;150:1015e11-1015e17.
8. Tarantini G, Ramondo A, Napodano M, et al: Myocardial perfusion grade and survival after percutaneous transluminal coronary angioplasty in patients with cardiogenic shock. Am J Cardiol 2004;93:1081-1085.
9. Tarantini G, Razzolini R, Cacciavillani L, et al: Influence of transmurality, infarct size, and severe microvascular obstruction on left ventricular remodeling and function after primary coronary angioplasty. Am J Cardiol 2006;98:1033-1040.
10. Wu E, Judd RM, Vargas JD, et al: Visualisation of presence, location, and transmural extent of healed Q-wave and non-Q-wave myocardial infarction. Lancet 2001;357:21-28.
11. Hombach V, Grebe O, Merkle N, et al: Sequelae of acute myocardial infarction regarding cardiac structure and function and their prognostic significance as assessed by magnetic resonance imaging. Eur Heart J 2005;26:549-557.
12. De Luca G, Suryapranata H, Stone G, et al: Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction. JAMA 2005;293:1759-1765.
13. Maioli M, Bellandi F, Leoncini M, Toso A, Dabizi RP: Randomized early versus late abciximab in acute myocardial infarction treated with primary coronary intervention (RELAx-AMI trial). J Am Coll Cardiol 2007;49:1517-1524.
14. Rakowski T, Zalewski J, Legutko J, et al: Early abciximab administration before primary percutaneous coronary intervention improves infarct-related artery patency and left ventricular function in high risk patients with anterior wall myocardial infarction: a randomized study. Am Heart J 2007;153:360-365.
15. Reimer KA, Jennings RB, Cobb FR, et al: Animal models for protection ischemic myocardium: results of the NHLBI Cooperative Study. Comparison of unconscious and conscious dog models. Circ Res 1985;56:651-665.
16. Fernandez-Avilés F, Alonso JJ, Pena G, et al: Primary optimal percutaneous coronary intervention versus facilitated intervention (tenecteplase plus stenting) in patients with ST-elevated acute myocardial infarction (GRACIA-2). Eur Heart J 2007, E-pub ahead of print.
17. Ross AM, Coyne KS, Reiner JS, et al: A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. PACT investigators. Plasminogen-activator Angioplasty Compatibility Trial. J Am Coll Cardiol 1999;34:1954-1962.
18. Petronio AS, Rovai D, Musumeci G, et al: Effects of abciximab on microvascular integrity and left ventricular functional recovery in patients with acute infarction treated by primary coronary angioplasty. Eur Heart J 2003;24:67-76.
19. Sciagrà R, Parodi G, Pupi A, et al: Gated SPECT evaluation of outcome after abciximab-supported primary infarct artery stenting for acute myocardial infarction: the scintigraphic data of the abciximab and carbostent evaluation (ACE) randomized trial. J Nucl Med 2005;46:722-727.
20. Montalescot G, Barragan P, Wittenberg O, et al: Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-1903.
21. Neumann FJ, Blasini R, Schmitt C, et al: Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 1998;98:2695-2701.
22. Reffelman T, Kloner RA: The 'no-reflow' phenomenon: basic science and clinical correlates. Heart 2002;87:162-168.
23. Costantini CO, Stone GW, Mehran R, et al: Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction. J Am Coll Cardiol 2004;44:305-312.
24. Rosenbaum PR: Observational Studies, ed 2. New York, Springer, 2002.
25. Vandenbroucke JP: When are observational studies as credible as randomised trials. Lancet 2004;363:1728-1731.
26. Concato J, Horwitz RI: Beyond randomised versus observational studies. Lancet 2004;363:1660-1661.
27. Piérard LA, Lancellotti P: The role of ischemic mitral regurgitation in the pathogenesis of acute pulmonary edema. N Engl J Med 2004;351:1627-1634.
28. Cerqueira MD, Weissman NJ, Dilsizian V, et al: Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professional from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002;105:539-542.
29. Moon JCC, Perez De Arenaza D, Elkington AG, et al: The pathologic basis of Q-wave and non-Q-wave myocardial infarction. A cardiovascular magnetic resonance study. J Am Coll Cardiol 2004;44:554-560.